Home › Companies › KARYOPHARM THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and KARYOPHARM THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024 (Item 5.07 on EDGAR). Page generated October 13, 2026.
Meeting of May 29, 2024: 8 items on KARYOPHARM THERAPEUTICS INC.’s Form 8-K, filed May 31, 2024: 5 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens
Proxy season: 2023-2024
Explore KARYOPHARM THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KARYOPHARM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 31, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Deepika R. Pakianathan | 55,942,175 | -- | -- | 11,898,716 | 22,984,379 | 82% | Not verified | — |
| Elect Director: Richard Paulson, M.B.A. | 56,105,696 | -- | -- | 11,735,195 | 22,984,379 | 83% | Not verified | — |
| Elect Director: Chen Schor, M.B.A., C.P.A. | 46,571,888 | -- | -- | 21,269,003 | 22,984,379 | 69% | Not verified | — |
| 2. The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. | 48,577,256 | 19,162,909 | 100,726 | -- | 22,984,379 | 72% | Approved | — |
| 3. The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. | 55,691,108 | 12,052,192 | 97,591 | -- | 22,984,379 | 82% | Approved | — |
| 4. The Company's stockholders approved a one-time stock option exchange program for non-executive officer employees. | 60,719,931 | 7,070,865 | 50,095 | -- | 22,984,379 | 90% | Approved | — |
| 5. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | 55,719,917 | 12,055,044 | 65,930 | -- | 22,984,379 | 82% | Approved | — |
| 6. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 87,747,448 | 2,519,068 | 558,754 | -- | -- | 97% | Approved | — |
Source: KARYOPHARM THERAPEUTICS INC., Form 8-K, filed with the SEC on May 31, 2024 — read the filing on EDGAR.
Each item below shows how the 121 asset managers that disclosed a KARYOPHARM THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KARYOPHARM THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: To elect the following three Class II directors nominees: Chen Schor, M.B.A., C.P.A.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Chen Schor, M.B.A., C.P.A.”): 46,571,888 for, 21,269,003 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 500,000 | Withhold |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 0 | 0 | 192,810 | Mixed |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 210,720 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 189,500 | Withhold |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 94,162 | Withhold |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 12,275,081 for, 1,200,933 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 740,000 for.
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect the following three Class II directors nominees: Deepika R. Pakianathan, Ph.D.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 55,942,175 for, 11,898,716 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 0 | 0 | 192,810 | Mixed |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,283,204 for, 192,810 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 740,000 for.
Combines 5 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: To elect the following three Class II directors nominees: Richard Paulson, M.B.A.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard Paulson, M.B.A.”): 56,105,696 for, 11,735,195 withheld, per its Form 8-K filed May 31, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,476,014 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 740,000 for.
Combines 3 wordings of this item as funds reported it.
92% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of our common stock available for issuance thereunder by 6,000,000 shares.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 500,000 | 0 | 0 | Against |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 192,810 | 0 | 0 | Mixed |
| ETF Series Solutions | 0 | 211,477 | 0 | 0 | Against |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 189,500 | 0 | 0 | Against |
| Fidelity | 75,903 | 51,077 | 0 | 0 | Mixed |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 89,853 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 0 | 64,636 | 0 | 0 | Against |
| Northern Trust | 0 | 43,876 | 0 | 0 | Against |
| Voya | 0 | 38,802 | 0 | 0 | Against |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 0 | 35,868 | 0 | 0 | Against |
| GPS Funds I | 0 | 29,892 | 0 | 0 | Against |
| ProShares | 0 | 23,266 | 0 | 0 | Against |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 17,929 | 0 | 0 | Against |
| DWS | 0 | 17,768 | 0 | 0 | Against |
| Nationwide | 3,344 | 14,410 | 0 | 0 | Mixed |
| Principal | 0 | 15,236 | 0 | 0 | Against |
Fund voting reports, all 38 managers: 11,906,361 for, 1,569,653 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Palo Alto Investors LP | 5,102,193 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 5,842,193 for.
Combines 4 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve a one-time stock option exchange program for non-executive officer employees.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“4. The Company's stockholders approved a one-time stock option exchange program for non-executive officer employees.”): 60,719,931 for, 7,070,865 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a one-time stock option exchange program for non-executive officer employees.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 94,162 | 0 | 0 | Against |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,203 | 551 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,367,561 for, 108,453 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 2,630,040 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 3,370,040 for.
Combines 2 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve an amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan to increase the number of shares of our common stock available for issuance thereunder by 5,000,000 shares.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,476,014 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 740,000 for.
Combines 4 wordings of this item as funds reported it.
82% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“5. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 55,719,917 for, 12,055,044 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,476,014 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Avidity Partners Management LP | 8,298,570 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 5,102,193 | 0 | 0 | 0 | For |
| Citadel | 2,747,093 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,630,040 | 0 | 0 | 0 | For |
| BlackRock | 2,438,439 | 0 | 0 | 0 | For |
| C WorldWide Asset Management Fondsmaeglerselskab A/S | 1,500,000 | 0 | 0 | 0 | For |
| State Street | 1,257,367 | 0 | 0 | 0 | For |
| Goldman Sachs | 917,173 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 900,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 868,130 | 0 | 0 | 0 | For |
| DE Shaw | 756,609 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| UBS | 628,256 | 0 | 0 | 0 | For |
| Northern Trust | 515,761 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 500,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 476,413 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 369,302 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| SEI | 211,188 | 0 | 0 | 0 | For |
| AllianceBernstein | 192,810 | 0 | 0 | 0 | For |
| Renaissance | 192,729 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 192,678 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 189,500 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 155,120 | 0 | 0 | 0 | For |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 122,621 | 0 | 0 | 0 | For |
Institutional-manager reports, all 94 managers: 33,342,346 for, 14,573 against, 600 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“6. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 87,747,448 for, 2,519,068 against — passed, per its Form 8-K filed May 31, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
| Principal | 15,236 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 13,476,014 for. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 740,000 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 117,710,263 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.94% |
| 2 | BlackRock | 1.46% |
| 3 | MUTUAL FUND SERIES TRUST | 0.96% |
| 4 | Delaware/Macquarie | 0.42% |
| 5 | Charles Schwab | 0.26% |
| 6 | Equitable | 0.19% |
| 7 | ETF Series Solutions | 0.18% |
| 8 | SEI | 0.18% |
| 9 | BRIDGEWAY FUNDS INC | 0.16% |
| 10 | Fidelity | 0.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Avidity Partners Management LP | 7.05% |
| 2 | Palo Alto Investors LP | 4.33% |
| 3 | Citadel | 2.33% |
| 4 | Eversept Partners, LP | 2.23% |
| 5 | BlackRock | 2.07% |
| 6 | C WorldWide Asset Management Fondsmaeglerselskab A/S | 1.27% |
| 7 | State Street | 1.07% |
| 8 | Goldman Sachs | 0.78% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.76% |
| 10 | MARSHALL WACE, LLP | 0.74% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Highbridge Capital Management, LLC | 8.28% | DEF14A |
| The Vanguard Group | 7.40% | 13G |
| J. Wood Capital Advisors LLC | 5.84% | DEF14A |
| S | 4.03% | 13G |
| Geode Capital | 2.14% | 13F |
| State Street | 1.94% | 13F |
| Millennium Management | 1.01% | 13F |
| Richard Paulson | 1.00% | DEF14A |
| D.E. Shaw | 0.82% | 13F |
| Northern Trust | 0.81% | 13F |
Percentages above are of 117,710,263 shares outstanding, as reported by KARYOPHARM THERAPEUTICS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KARYOPHARM THERAPEUTICS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.
At KARYOPHARM THERAPEUTICS INC.'s shareholder meeting held May 29, 2024, in the 2023-2024 proxy season, 121 asset managers reported how they voted in their SEC Form N-PX filings, covering 937 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — KARYOPHARM THERAPEUTICS INC.'s filing reports the proposal as approved, with 82% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KARYOPHARM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 31, 2024.
KARYOPHARM THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).
Download data (CSV): ballot items · votes by manager · column guide.